25 results about "Bladder tumor" patented technology

The application discloses a bladder tumor specimen extractor which comprises an adjusting transmission assembly capable of controlling preliminary cutting, a separating assembly capable of separating a tissue part and a liquid part of the bladder tumor and an operating handle. The application belongs to the technical field of bladder tumor surgery. When the bladder tumor temporarily stays on a tissue liquid passing layer, the removed bladder tumor can be punctured by a plurality of groups of puncture heads, so that the tissue part of the bladder tumor is blocked by the tissue liquid passing layer, and the tissue liquid and the plasma part of the bladder tumor can pass through the tissue liquid passing layer and enter a liquid storage bag. After sampling is completed, medical staff can take out the liquid storage bag to sample the tissue liquid and the plasma part of the bladder tumor, and the tissue part of the bladder tumor can be sampled from the tissue liquid passing layer. The application provides a brand-new bladder tumor sampling experience, greatly reduces the possibility of tissue liquid and plasma remaining in the bladder and brings convenience to medical staff.

The application relates to the field of biological preparations, and particularly discloses an immunochromatographic reagent for detecting malignant tumors in urine and application thereof, which is used for solving the problems of poor recognition of tumor specific epitopes, heavy background interference, spectrum overlap and high subjectivity of artificial judgment in the single staining and color development of acridine orange in the detection of urinary exfoliative cells of bladder cancer. The color development reagent comprises A reagent, B reagent, C reagent and D reagent. The A reagent is provided with an antibody complex for target antigens of bladder tumor cells in urine exfoliation and acridine orange. The B reagent comprises a fluorescently labeled secondary antibody composition corresponding to the A reagent and an enzyme-labeled secondary antibody-tyramide deposition amplification composition. In the application, AI imaging analysis is adopted to calibrate layered recognition labels and acridine orange staining negative and positive labels. Through multi-target immunochromatography, two sets of color separation amplification schemes and AI imaging analysis, the application improves the recognition ability of bladder tumor specific epitopes, the image quality and the image analysis accuracy in the detection of urinary exfoliative cells.

The invention provides a sorbitol and mannitol flushing fluid for urinary surgery. The invention relates to a freeze-dried powder injection, which comprises 20 to 50 grams of sorbitol, 10 to 30 grams of mannitol, 5 to 10 grams of sodium bicarbonate and 0.5 to 2 grams of sodium citrate in every 1000 milliliters of the freeze-dried powder injection, and the pH value of the freeze-dried powder injection is adjusted to 7.2 to 7.4. The preparation method comprises the following steps: heating distilled water to 80 DEG C, sequentially adding the components, continuously stirring until the components are completely dissolved, cooling to room temperature, fixing the volume to 1000ml, adjusting the pH value by using a 5mol / L sodium hydroxide solution, finally sterilizing by using a 0.22-micron microporous filter membrane, and packaging in a sterilized glass bottle. The flushing fluid can effectively dissolve blood clots, stones and necrotic tissues in an operation field by utilizing the high osmotic pressure characteristics of the sorbitol and the mannitol, so that the operation field is kept clear. The flushing fluid disclosed by the invention shows an excellent flushing effect and good safety in urinary surgery operations such as transurethral bladder tumor electrocision, flexible ureteroscope calculus removal and the like.

This invention belongs to the field of molecular biology and medical detection technology, and discloses a bladder cancer-specific nucleic acid aptamer, nucleic acid aptamer derivatives, and their applications. The nucleotide sequences of the nucleic acid aptamer are shown in SEQ ID NO: 1, 2, and 3. This invention screened three monoclonal nucleic acid aptamer DNA chains from bladder cancer tissue samples using the exponential enrichment systematic evolution (SELEX) technique and identified two target proteins that bind to these three nucleic acid aptamers. The nucleic acid aptamers specifically target the target proteins CAPRIN1 and FXR1 on the surface of bladder tumor cells. The nucleic acid aptamers obtained by this invention have advantages such as high affinity and specificity, no immunogenicity, simple chemical synthesis, stability, and ease of storage and labeling, providing a new molecular tool for the early diagnosis and targeted therapy of bladder cancer.

The present invention relates to a method for providing information for predicting the likelihood of bladder cancer recurrence, which provides information that patients who have undergone transurethral resection of a bladder tumor and test positive for suspicious high-grade urothelial carcinoma (SHGUC) or high-grade urothelial carcinoma (HGUC) in a urine cytology test have a higher likelihood of bladder cancer recurrence compared with patients who do not test positive.

The invention discloses a bladder tumor cell strain with squamous differentiation characteristics and application thereof, and relates to the technical field of biological medicines. Wherein the bladder tumor cell strain is selected from one of a human bladder tumor cell strain MP-MGHU3-LT, a human bladder tumor cell strain UCSD-MGHU3-LT, a human bladder tumor cell strain UCSD-RT4-LT and a mouse bladder tumor cell strain mUCMP, the bladder tumor cell strains are all preserved in the China Center for Type Culture Collection, and the preservation numbers of the bladder tumor cell strains are respectively CCTCC NO: C2025241, CCTCC NO: C2025252, CCTCC NO: C2025253 and CCTCC NO: C2025254. The bladder tumor cell strain provided by the invention has squamous differentiation characteristics, and can be applied to model construction, mechanism research and drug screening of bladder cancer with squamous differentiation characteristics.

This invention discloses a bladder tumor segmentation method and system based on parallel branch-focused linear attention, belonging to the field of bladder tumor segmentation technology. The method includes: a main branch extracting specific morphological and structural features from cystoscopy images, combined with a novel focused linear attention module to achieve high efficiency and expressiveness; a fast convolutional branch capturing spatial details to compensate for the limitations of the main branch in full-size prediction; a spatial channel reconstruction convolutional residual module reducing redundant computation and promoting representative feature learning, thus lowering complexity and computational cost; and a prediction head connecting the main branch and the fast convolutional branch, fusing the coarse-grained features extracted by the main branch with the fine-grained features extracted by the fast convolutional branch to predict the segmentation map. This invention improves the morphological specificity of bladder tumors, the distinction between bladder tumors and normal tissues, and the problem of blurred bladder tumor boundaries, significantly improving computational efficiency.

The invention discloses a bladder tumor specimen extractor which comprises an adjusting transmission assembly capable of controlling preliminary dicing, a separating assembly capable of separating a tissue part and a liquid part of a bladder tumor and an operating handle. The invention belongs to the technical field of bladder tumor surgery. When the bladder tumor temporarily exists on the tissue fluid passing layer, the puncture heads can puncture the taken-down bladder tumor, so that the tissue part of the bladder tumor is blocked through the tissue fluid passing layer, and the tissue fluid and plasma part of the bladder tumor can penetrate through the tissue fluid passing layer and enter the fluid storage bag; medical staff can sample tissue fluid and plasma parts of the bladder tumor by taking down the fluid storage bag, the tissue part of the bladder tumor can be sampled from the tissue fluid passing layer, brand-new bladder tumor sampling experience is provided, the possibility that the tissue fluid and the plasma are left in the bladder is greatly reduced, and convenience is brought to the medical staff.

The invention belongs to the technical field of biological medicines, and particularly relates to a bladder cancer targeted nano-drug and a preparation method thereof. The drug is constructed by taking a chemotherapeutic drug gemcitabine-loaded poly (lactic-co-glycolic acid) nanoparticle as a core and assembling two functional components, namely a gadolinium-doped zinc-aluminum layered double hydroxide folic acid conjugate and a bismuth-tellurium alloy nano-cluster hyaluronic acid compound, on the surface of the nanoparticle. During preparation, the drug-loaded nanoparticles are prepared by adopting a multiple emulsion solvent evaporation method, and then the two functional compounds are co-assembled on the surfaces of the drug-loaded nanoparticles by utilizing electrostatic interaction to form the multifunctional hybrid shell layer. The nano-drug integrates multiple functions such as active targeting, microenvironment response drug release, multi-mode imaging, chemotherapy and chemical kinetics combined treatment and radiotherapy sensitization, enrichment and permeation of the drug at a bladder tumor part can be remarkably improved, efficient synergistic treatment is achieved, system toxicity is reduced, and the nano-drug is particularly suitable for perfusion treatment in the bladder.

The application belongs to the field of molecular biology and medical detection technology, and discloses a bladder cancer nucleic acid aptamer, a nucleic acid aptamer derivative and application thereof.The nucleotide sequence of the nucleic acid aptamer is shown as SEQ ID NO:6.Through an exponential enrichment system evolution (SELEX) technology, a single clone nucleic acid aptamer DNA chain of a bladder cancer tissue sample is screened, and two target proteins targeted and combined with the nucleic acid aptamer are identified.The nucleic acid aptamer can specifically target the target proteins CAPRIN1 and FXR1 on the surface of bladder tumor cells.The nucleic acid aptamer screened in the application has the advantages of high affinity and specificity, no immunogenicity, simple chemical synthesis, stability, easy preservation and labeling, and the like, and provides a new molecular tool for early diagnosis and targeted treatment of bladder cancer.

Provided herein are methods and systems for cancer detection and monitoring. The methods may include minimal residual disease analysis. The methods may include using nucleic acids from a urine sample or a urine cell pellet sample. The methods may include assaying nucleic acids in urine to detect a set of biomarkers from the sample. The methods may include monitoring a subject after transurethral bladder tumor resection.

The application belongs to the field of intelligent medical treatment, and particularly relates to a bladder tumor image segmentation method, device, medium and program product. The method comprises the following steps: S101, acquiring an image of a bladder tumor patient; S102, inputting the image into a 2D U-Net for tumor segmentation to obtain a 2D segmentation result; S103, based on the 2D segmentation result, traversing the shape of the tumor, if the current tumor shape is regular, inputting the image into a 3D U-Net for tumor segmentation to obtain a 3D segmentation result, and taking the segmentation result of the current tumor in the 3D segmentation result; if the tumor shape is irregular, taking the segmentation result of the current tumor in the 2D segmentation result, and after the traversal is completed, merging and outputting the segmentation results of multiple tumors. The application can optimize the segmentation performance by using the complementary advantages of the 2D-3D method, and obtain better segmentation results.

The invention discloses a targeted drug delivery system in a bladder. The targeted drug delivery system comprises a reagent A and a reagent B, the reagent A is a biological micromotor, platelets are taken as a natural carrier, and streptavidin is bridged and coupled with biotinylation modified urease to serve as a driving component to entrap active components; the reagent B is a urea solution. According to the invention, the natural characteristics of platelet chemotaxis tumor inflammation microenvironment are utilized to realize specific enrichment of motors in a bladder tumor area; after urea perfusion, urease catalyzes urea to generate gas power to push the motor to move, meanwhile, compact extracellular matrixes are slightly loosened, the motor is assisted to penetrate and reach the interior of a tumor and release drugs, and the delivery efficiency and targeting performance of the drugs in the bladder are remarkably improved.

Some embodiments of the present disclosure are directed to methods and compositions for the treatment of tumors, using a combination of immunotherapeutic agents and tumor-targeting viral capsid protein assemblages comprising anti-cancer molecules conjugated to viral capsid proteins.

The invention provides a solution to deficiencies in innate immune cell targeting in solid tumors, including bladder cancer, through IL-18 or IL-15 Tetra protein targeted Killer Engagers (TetraKEs). These leverage CD16 and CD56 to enhance natural killer (NK) cell targeting of Nectin-4+ bladder tumor cells, offering a novel immunotherapeutic approach.

The application provides a freezing device and a lithotripsy device. The freezing device is used for freezing a calculus or a bladder tumor. The freezing device comprises a main machine, a freezing catheter and a freezing head. The main machine is used for providing a freezing medium. The freezing catheter is used for transmitting the freezing medium. The main machine comprises an input port and an output port. Two ends of the freezing catheter are connected to the output port and the input port of the main machine respectively. The freezing head is in heat exchange connection with the freezing catheter. The freezing head is used for contacting the calculus or the bladder tumor. The freezing of the calculus can increase the brittleness of the calculus, and the efficiency of the lithotripsy is improved.

The invention belongs to the technical field of molecular biology and medical detection, and discloses a bladder cancer nucleic acid aptamer, a nucleic acid aptamer derivative and application thereof. The nucleotide sequence of the nucleic acid aptamer is as shown in SEQ ID NO: 6. A monoclonal nucleic acid aptamer DNA chain of a bladder cancer tissue sample is screened through an exponential enrichment systematic evolution (SELEX) technology, two target proteins in targeted combination with the nucleic acid aptamer are identified, and the nucleic acid aptamer can specifically target the target proteins CAPRIN1 and FXR1 on the surfaces of bladder tumor cells. The nucleic acid aptamer obtained through screening has the advantages of being high in affinity and specificity, free of immunogenicity, simple and stable in chemical synthesis, easy to store and mark and the like, and a new molecular tool is provided for early diagnosis and targeted therapy of bladder cancer.

This prostate treatment method includes an insertion step of inserting a balloon coated with a medicine into a urethra, an expansion step of expanding the balloon in a prostate part where the prostate is located in the urethra, and a step of injecting the medicine by piercing the prostate part with a microneedle attached to the surface of the balloon. This bladder tumor treatment method is for treating a bladder tumor having a tumor bulging part and a tumor bottom part, the bladder tumor treatment method being provided with a cutting step of cutting off the tumor bulging part, and a freezing step of freezing the tumor bottom part.

Recombinant BCG, a preparation method therefor and an application thereof. A shuttle plasmid that can express a FimH protein on the surface of BCG is constructed, and a gene fragment that expresses the FimH protein is transformed into wild-type BCG to thereby obtain recombinant BCG. Upon verification, the recombinant BCG can express the FimH protein on the surface of BCG; therefore, the BCG can specifically bind to subjects that can selectively bind to the FimH protein. The recombinant BCG can also enhance the local innate immune effect and adaptive immune effect induced by BCG and the anti-tumor effect of peripheral blood mononuclear cells, and also significantly improves the effect of BCG against bladder tumors, and is used to treat bladder tumors.

This invention relates to the field of bladder CT image analysis technology, specifically to a method, device, and system for auxiliary examination of bladder tumors. This invention performs feature matching based on similar characteristics of the bladder boundary morphology in CT images from different scanning stages, providing reference information for subsequent pixel matching within the bladder region. Simultaneously, leveraging the ability to clearly observe tumor features in delayed-phase images, it combines pixel matching information within the bladder region to assess the likelihood of abnormal tumors in CT images from other scanning stages. Finally, it comprehensively analyzes CT images from all scanning stages to assess and label the patient's bladder tumor probability, avoiding poor tumor analysis results caused by the poor matching performance of traditional matching algorithms, thus improving the auxiliary examination effect of bladder tumors.

The invention discloses an AI-based bladder tumor microscopic examination auxiliary diagnosis and operation planning system, and relates to the technical field of medical artificial intelligence. The system comprises an image acquisition module, an AI diagnosis module, an operation planning module and a human-computer interaction interface, real-time high-precision analysis and diagnosis of cystoscope images are realized through an improved HRNetV2 neural network and multi-resolution feature fusion, and exosome spectral analysis is integrated to assist in early screening. The system can automatically generate a personalized surgical scheme based on a diagnosis result, supports three-dimensional reconstruction and surgical path planning, and can be in butt joint with a flexible surgical robot to execute accurate operation. The bladder tumor diagnosis accuracy and the operation safety are effectively improved, dependence on external labeled data is reduced, and good clinical applicability and popularization value are achieved.

The invention provides a bladder cancer adjuvant therapy curative effect prediction method and system based on multi-modal feature fusion, and the method comprises the steps: extracting bladder cancer preoperative CTU image modal features: extracting iconomics features and topology features of a bladder tumor region, and constructing a high-dimensional image feature project; extracting preoperative pathological WSI modal features of bladder cancer: performing single-cell-level pathological feature extraction on a full-digital pathological section, and constructing a pathological high-throughput feature project; collecting baseline clinical features of a patient, and constructing a standardized clinical feature matrix; the method comprises the following steps: performing multi-modal feature fusion on image, pathology and clinical heterogeneous data in a high-dimensional space, reserving an interaction relationship among modal features, constructing and training an auxiliary curative effect prediction model based on a multi-layer perceptron, and performing bladder cancer auxiliary treatment curative effect prediction based on the auxiliary curative effect prediction model. According to the method, quantitative support can be provided for clinically formulating individualized treatment strategies, and the recognition efficiency of NAT adaptive crowds is more expected to be improved.

The invention relates to the technical field of immunodiagnosis, and discloses a preparation method and application of a colloidal carbon labeled antibody for detecting a bladder tumor antigen. The preparation method of the colloidal carbon labeled antibody comprises the following steps: adding polyvinylpyrrolidone into a carbon powder aqueous dispersion, adjusting the pH value to 6.0-6.5, then adding an anti-bladder tumor antigen antibody, and labeling; adding a serum albumin aqueous solution, stirring and mixing, adding a polyethylene glycol aqueous solution, stirring and mixing, adding a cocamidopropyl betaine aqueous solution, stirring and mixing, and separating out a product. The colloidal carbon labeled antibody prepared by the method can improve the detection sensitivity of a colloidal carbon immunochromatography technology on the bladder tumor antigen, and is beneficial to improving the detection accuracy and reducing the possibility of leak detection while realizing the rapid and convenient detection of the bladder tumor antigen.

The invention relates to the field of biological agents, particularly discloses an immune color developing reagent for detecting malignant tumors in urine and application of the immune color developing reagent, and is used for solving the problems that in bladder cancer urine exfoliated cell detection, an acridine orange single staining color developing image is poor in bladder tumor specific epitope recognition, heavy in background interference and high in spectrum overlapping and manual interpretation subjectivity. The color developing reagent comprises a reagent A, a reagent B, a reagent C and a reagent D. The reagent A is provided with an antibody complex and acridine orange aiming at tumor cell target antigens of bladder parts in urine shedding, and the reagent B comprises a fluorescently-labeled secondary antibody composition and an enzyme-labeled secondary antibody-tyramine deposition amplification composition corresponding to the reagent A, and the reagent D is provided with an enzyme-labeled secondary antibody-tyramine deposition amplification composition corresponding to the enzyme-labeled secondary antibody-tyramine deposition amplification composition corresponding to the reagent D. In the application, AI imaging analysis is adopted, and layered identification labels and acridine orange dyeing negative and positive labels are calibrated; through multi-target immune color development, two sets of color separation amplification schemes and AI imaging analysis, the bladder tumor specific epitope recognition capability, the image quality and the image analysis accuracy of urine cast-off cell detection are improved.

The invention belongs to the technical field of resectoscopes, and particularly relates to a bladder tumor resectoscope which comprises an endoscope and an operation assembly, the endoscope is connected with the operation assembly, the operation assembly comprises a sleeve, the sleeve is connected with a first connecting block, the first connecting block is connected with a second connecting block, and the second connecting block is connected with a third connecting block. The second connecting block is connected with the operator body, the pushing finger ring is installed at the bottom of the operator body, the electric knife can be installed below the endoscope through the limiting sleeve installed below the endoscope, the endoscope and the electric knife are directly installed in the inner sheath, compared with the prior art, the outer sheath part is removed, and the operation is convenient. The size of the resectoscope is reduced, surgical wounds are reduced, the guide pipe installed on the inner sheath can bear the flexible object taking clamping jaw, the tumor living body subjected to electric resection can be taken out of the body through the flexible object taking clamping jaw, human tissue can be clamped through the flexible object taking clamping jaw, and therefore the cutting accuracy of the electric resectoscope can be improved.